Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Products under Development by Stage of Development | 7 | 1 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Products under Development by Therapy Area | 8 | 1 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Products under Development by Indication | 9 | 1 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Products under Development by Companies | 12 | 2 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Products under Development by Universities/Institutes | 14 | 2 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 1 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Companies Involved in Therapeutics Development | 21 | 3 |
| Celgene Corporation | 21 | 1 |
| Eisai Co., Ltd. | 22 | 1 |
| OPKO Health, Inc. | 23 | 1 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Drug Profiles | 24 | 7 |
| bentamapimod Drug Profile | 24 | 1 |
| CC-539 Drug Profile | 25 | 1 |
| CC-90001 Drug Profile | 26 | 1 |
| ER-358063 Drug Profile | 27 | 1 |
| Small Molecules to Activate JNK-1, JNK-2 and p38 MAP Kinase for Oncology Drug Profile | 28 | 1 |
| Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure Drug Profile | 29 | 1 |
| SR-3306 Drug Profile | 30 | 1 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Dormant Projects | 31 | 1 |
| Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) Featured News &Press Releases | 32 | 1 |
| Oct 07, 2010: Richter Announces The Acquisition Of PregLem | 32 | 1 |
| Appendix | 33 | 2 |
| Methodology | 33 | 1 |
| Coverage | 33 | 1 |
| Secondary Research | 33 | 1 |
| Primary Research | 33 | 1 |
| Expert Panel Validation | 33 | 1 |
| Contact Us | 33 | 1 |
| Disclaimer | 34 | 1 |